Laboratory Corp. of America Holdings  

(Public, NYSE:LH)   Watch this stock  
Find more results for L & B Development�
+0.64 (0.53%)
Nov 25 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 121.11 - 122.39
52 week 99.89 - 131.19
Open 121.35
Vol / Avg. 581,459.00/1.12M
Mkt cap 12.26B
P/E 26.94
Div/yield     -
EPS 4.52
Shares 101.20M
Beta 0.85
Inst. own 97%
Feb 18, 2016
Q4 2015 Laboratory Corporation of America Holdings Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 10, 2015
Laboratory Corporation of America Holdings at Credit Suisse Healthcare Conference
Oct 26, 2015
Q3 2015 Laboratory Corporation of America Holdings Earnings Release
Oct 26, 2015
Q3 2015 Laboratory Corporation of America Holdings Earnings Call - Webcast
Sep 17, 2015
Laboratory Corporation of America Holdings at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 6.61% 8.53%
Operating margin 13.24% 15.14%
EBITD margin - 19.52%
Return on average assets 4.25% 7.19%
Return on average equity 12.66% 19.25%
Employees 36,000 -
CDP Score - -


BURLINGTON, NC 27215-5837
United States - Map
+1-336-2291127 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease. The Company manages its operations through two segments: the Clinical diagnostics laboratory segment, which includes core testing, as well as genomic and esoteric testing; and the Other segment, which consists of the Company's non-United States clinical diagnostic laboratory operations in Ontario, Canada. It also provides specialty testing services in the areas of allergy, clinical trials, diagnostic genetics, women's health, cardiovascular disease, identity, forensics, infectious disease, endocrinology, oncology, coagulation, occupational testing and pain management.

Officers and directors

David P. King Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Glenn A. Eisenberg Chief Financial Officer, Executive Vice President
Bio & Compensation  - Reuters
Deborah L. Keller Tanner Chief Executive Officer - Covance Drug Development (Covance)
Age: 52
Bio & Compensation  - Reuters
William E. Klitgaard President- Enlighten Health
Age: 62
Bio & Compensation  - Reuters
Lisa J. Uthgenannt Chief Human Resource Officer
Age: 54
Bio & Compensation  - Reuters
James T. Boyle Jr. Executive Vice President and Chief Executive Officer- LabCorp Diagnostics
Age: 58
Bio & Compensation  - Reuters
Edward T. Dodson Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
Age: 61
Bio & Compensation  - Reuters
Lance V. Berberian Senior Vice President, Chief Information Officer
Age: 52
Bio & Compensation  - Reuters
F. Samuel Eberts III Senior Vice President, Chief Compliance Officer, Secretary, Chief Legal Officer
Age: 55
Bio & Compensation  - Reuters
Mark Elliott Brecher M.D. Senior Vice President, Chief Medical Officer
Age: 58
Bio & Compensation  - Reuters